摘要
抗血管生成基因治疗是一有希望的抑制肿瘤生长及转移的方法。在实验中构建了含有人内皮抑素 (endo statin)基因的重组腺相关病毒载体rAAV -hE。所包装纯化的重组病毒滴度达 0 5× 10 12 v g /ml。rAAV -hE能有效感染培养细胞 ,EIA法检测培养液上清中内皮抑素浓度达 36 4 2ng/ml。rAAV介导所表达的内皮抑素对人脐静脉内皮细胞 (ECV - 30 4 )和牛毛细血管内皮细胞 (BCE)具有抗增殖抑制作用 ,抑制率分别为 6 8 1%和 4 1 6 %。此结果为进一步的动物实验奠定了基础 。
Antiangiogenesis gene therapy is a promising approach to inhibit tumor growth and metastases.We have constructed a recombinant adeno-associated viral vector,rAAV,which encodes a secretable form of human endostatin(hE).The titer of rAAV-hE was 0.5×10 12 v.g./ml.The rAAV-hE transduced the BHK-21 cells efficiently and EIA showed that the endostatin expression level was 36.42ng/ml.The supernatant from BHK-21 cells transduced by rAAV-hE showed inhibition activity on ECV-304 cell(HUVEC)and bovine capillary endothelial cell proliferation in vitro with the inhibitory rate of 68.1% and 41.6% respectively.These results offered a preliminary data for turther animal study and demonstrated the potential of recombinant adeno-associated viral vector-mediated antiangiogenic gene therapy in cancer therapy
出处
《病毒学报》
CAS
CSCD
北大核心
2002年第3期235-239,共5页
Chinese Journal of Virology
基金
"八六三"高科技发展计划基因治疗重大关键技术资助项目 ( 863 -BH0 3 -0 5 -0 2 )